Pelaz García, BeatrizCorrea Paz, ClaraPérez Mato, MaríaKurisky, Brian PatrickZhang, IssanMarie, Pauline P.Hervella, PabloRubio, MarinaMaysinger, DusicaVivien, DenisPino González de la Higuera, Pablo Alfonso delPolo Tobajas, EsterMigliavacca, MartinaCampos Pérez, Francisco2024-04-252024-04-252024Migliavacca, M., Correa-Paz, C., Pérez-Mato, M., Bielawski, P.B., Zhang, I., Marie, P., Hervella, P., Rubio, M., Maysinger, D., Vivien, D., Pino, P. del, Pelaz, B., Polo, E., Campos, F. (2024). Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke . "Journal of Nanobiotechnology", vol. 22, 101477-3155http://hdl.handle.net/10347/33665Intravenous administration of fibrinolytic drugs, such as recombinant tissue plasminogen activator (rtPA) is the standard treatment of acute thrombotic diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short plasma half-lives and risk of hemorrhagic transformations. Platelet membrane-based nanocarriers have received increasing attention for ischemic stroke therapies, as they have natural thrombus-targeting activity, can prolong half-life of the fibrinolytic therapy, and reduce side effects. In this study we have gone further in developing platelet-derived nanocarriers (defined as cellsomes) to encapsulate and protect rtPA from degradation. Following lyophilization and characterization, their formulation properties, biocompatibility, therapeutic effect, and risk of hemorrhages were later investigated in a thromboembolic model of stroke in mice.eng© The Author(s) 2023. Open Accesshttp://creativecommons.org/licenses/by-nc-nd/4.0/Thrombolytic therapyischemic strokeCellsomeslyophilized platelet-derived nanocarriersictus cerebral320507 Neurología2306 Química orgánicajournal article10.1186/s12951-023-02206-5open access